Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 339

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 339
---
063)(61,938)Proceeds from maturities of investments42,497 — Purchase of property and equipment(167)(792)Payments made for additions to intangible assets— (10,000)Net cash used in investing activities(22,733)(72,730)Financing activitiesProceeds from issuance of common stock pursuant to equity plans15,047 8,496 Net cash provided by financing activities15,047 8,496 Effect of exchange rate on cash, cash equivalents and restricted cash3,281 (6)Net increase (decrease) in cash, cash equivalents and restricted cash5,674 (52,831)Cash, cash equivalents and restricted cash at beginning of period222,928 286,326 Cash, cash equivalents and restricted cash at end of period$228,602 $233,495  Supplemental disclosure of cash flow information:Operating cash flows paid for operating lease$1,147 $602 Cash paid for interest$6,325 $6,325 Cash paid for income taxes$1,647 $339 Non-cash operating, investing and financing activities:Accrued milestone payments classified as intangible assets, net$— $10,000 Right-of-use assets obtained in exchange for lease liabilities$1,673 $8,896 Decrease in ROU assets and lease liabilities due to lease modification$649 $723 Stock-based compensation capitalized to inventory$302 $694 Conversion of convertible notes, net into shares of common stock$9 $— 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Mirum Pharmaceuticals, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Description of Business

Mirum Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on May 2, 2018, and is headquartered in Foster City, California. The Company is a biopharmaceutical company dedicated to transforming the treatment of rare diseases.The Company has three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), Cholbam® (cholic acid) capsules (“Cholbam”), and Chenodal® or CTEXLI® (chenodiol) tablets (“Chenodal” or “Ctexli”). Livmarli is approved for the treatment of cholestatic pruritus in